{
    "clinical_study": {
        "@rank": "159821", 
        "arm_group": [
            {
                "arm_group_label": "SOF/LDV+RBV", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive SOF/LDV plus RBV for 8 weeks."
            }, 
            {
                "arm_group_label": "SOF/LDV+GS-9669 250 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive SOF/LDV plus GS-9669 250 mg for 8 weeks."
            }, 
            {
                "arm_group_label": "SOF/LDV+GS-9669 500 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive SOF/LDV plus GS-9669 500 mg for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV)\n      fixed-dose combination (FDC) plus ribavirin (RBV) or SOF/LDV plus GS-9669 in treatment-naive\n      or treatment-experienced participants with chronic genotype 1 HCV infection.  A total of 90\n      participants are planned to be enrolled in the study for 8 weeks of treatment, approximately\n      60 having had prior treatment with a regiment containing pegylated interferon (PEG) and RBV\n      for \u2265 12 weeks. Randomization will be stratified by treatment-naive versus\n      treatment-experienced and by HCV genotype (1a versus 1b)."
        }, 
        "brief_title": "Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18, with chronic genotype 1 HCV infection\n\n          -  Documented HCV treatment-na\u00efve or treatment-experienced subjects who failed previous\n             PEG+RBV regimen\n\n          -  HCV RNA > 10,000 IU/mL at Screening\n\n          -  Presence of compensated cirrhosis\n\n          -  Screening laboratory values within defined thresholds\n\n          -  Use of two effective contraception methods if female of childbearing potential or\n             sexually active male\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  Co-infection with HIV or hepatitis B virus (HBV)\n\n          -  Current or prior history of clinical hepatic decompensation\n\n          -  Chronic use of systemic immunosuppressive agents\n\n          -  History of clinically significant illness or any other medical disorder that may\n             interfere with subject treatment, assessment or compliance with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984294", 
            "org_study_id": "GS-US-337-0133"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SOF/LDV+RBV", 
                    "SOF/LDV+GS-9669 250 mg", 
                    "SOF/LDV+GS-9669 500 mg"
                ], 
                "description": "sofosbuvir (SOF) 400 mg/ledipasvir (LDV) 90 mg fixed dose combination (FDC) tablet administered orally once daily", 
                "intervention_name": "SOF/LDV", 
                "intervention_type": "Drug", 
                "other_name": "GS-7977/GS-5885"
            }, 
            {
                "arm_group_label": "SOF/LDV+RBV", 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug", 
                "other_name": "Ribasphere\u00ae"
            }, 
            {
                "arm_group_label": [
                    "SOF/LDV+GS-9669 250 mg", 
                    "SOF/LDV+GS-9669 500 mg"
                ], 
                "description": "GS-9669 250 mg tablet(s) administered orally once daily", 
                "intervention_name": "GS-9669", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV genotype 1", 
            "HCV", 
            "Sustained Virologic Response", 
            "Direct-Acting Antiviral", 
            "Combination Therapy", 
            "GS-7977", 
            "GS-5885", 
            "Ribavirin", 
            "Open Label", 
            "Sofosbuvir", 
            "Treatment-Naive", 
            "Protease Inhibitors", 
            "PI", 
            "Treatment experienced", 
            "Cirrhotic"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78215"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Rob Hyland, DPhil", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study medication.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Week 12"
            }, 
            {
                "measure": "Proportion of participants who discontinue study drug due to an adverse event", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984294"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with sustained virologic response (SVR) at 2, 4, 8, and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8, and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Weeks 2, 4, 8, and 24"
            }, 
            {
                "description": "Viral breakthrough is defined as HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 8"
            }, 
            {
                "description": "Viral relapse is defined as HCV RNA \u2265 LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Week 8 to post-treatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}